Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07207395 · ClinicalTrials.gov registry record · Phase 2

A Study of Orally Administered JBI-802 Alone or in Combination With Pembrolizumab for Patients With Non-small Cell Lung Cancer With an STK11 Mutation.

A Phase 2 study of Lung Cancer (NSCLC), sponsored by The Christ Hospital.

Recruiting
Registry status
Phase 2
Development phase
30
Enrollment target
1
Study location

NCT07207395 is a Phase 2 study of Lung Cancer (NSCLC) that is actively recruiting participants, run by The Christ Hospital. The registered enrollment target is 30 participants, below the 211-participant average among 7 other Lung Cancer (NSCLC) trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07207395, a Phase 2 study of Lung Cancer (NSCLC), is actively recruiting participants, sponsored by The Christ Hospital.

RECRUITING
Registry status
Phase 2
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to determine the overall safety and tolerability of JBI-802 as single agent and in combination with Pembrolizumab.

Conditions Studied

Lung Cancer (NSCLC)

Interventions

  • DRUG Pembrolizumab
  • DRUG JBI-802

Study Locations (1)

Ohio

  • The Christ Hospital - Cincinnati

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2025-04-29
Est. Completion 2028-10
Phase Phase 2

Sponsor

The Christ Hospital

13 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07207395

The ClinicalTrials.gov registry entry for NCT07207395 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 211-participant average among 7 other Lung Cancer (NSCLC) trials with a reported enrollment target (86% lower). The listed sponsor is The Christ Hospital, which has 13 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Lung Cancer (NSCLC) appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.

NCT07207395 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.

Frequently Asked Questions

What is clinical trial NCT07207395 about?

NCT07207395 is a clinical study titled "A Study of Orally Administered JBI-802 Alone or in Combination With Pembrolizumab for Patients With Non-small Cell Lung Cancer With an STK11 Mutation.". The purpose of this study is to determine the overall safety and tolerability of JBI-802 as single agent and in combination with Pembrolizumab.

What is the current status of trial NCT07207395?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2025-04-29. Estimated completion is 2028-10.

What conditions does trial NCT07207395 study?

This clinical trial studies the following conditions: Lung Cancer (NSCLC).

What interventions are being tested in trial NCT07207395?

The interventions under investigation include: Pembrolizumab (DRUG), JBI-802 (DRUG).

Who is sponsoring clinical trial NCT07207395?

This trial is sponsored by The Christ Hospital, which has 13 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07207395 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Lung Cancer (NSCLC)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Lung Cancer (NSCLC)

All registered trials for this condition

Ohio

All trials with a study site in Ohio

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.